All filters
Slidesets
Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others- Andre Boonstra, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Entry inhibition- Stephan Urban, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
CCC – DNA inhibition- Anuj Gaggar, MD, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
RNA interference- Bill Symonds, PharmD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Other virological mechanisms- Stephen Locarnini, BSc, PhD, MBBS, FRCP
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Innovative trial design- Henry Lik Yuen Chan
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Combination therapy how to navigate in a minefield of efficacy and toxicity?- Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Hepatitis E in HIV- Kenneth Sherman, MD, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
EASL highlights 2017- Jürgen Rockstroh, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Management of end-stage liver disease in HIV patients- Ana Morbey, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
New insights in management of HIV/HBV co-infected patients- Juan Berenguer, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HBV cure: what is coming in 5 – 10 years?- Patrick Kennedy, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance- Francesca Ceccherini– Silberstein, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Special considerations before / during / after DAA therapy- Kosh Agarwal, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Virologist's perspective - Charles Boucher, MD, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)- Mark Nelson, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Pharmacologist's perspective- David Back, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Are there any special populations in treatment of HCV left?- Douglas Dieterich, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. Valente
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. Buggish
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017